{"data":{"id":"us-ok/okla.-stat.-tit.-59-59-355.4","jurisdiction":"us-ok","citation":"Okla. Stat. tit. 59, § 59-355.4","heading":"Substituting interchangeable biological products for","body":"prescribed biological products.\n\nA. For the purposes of this section:\n\n1. \"Biological product\" has the same meaning given to that term\n\nin 42 U.S.C., Section 262; and\n\n2. \"Interchangeable biological product\" means a biological\n\nproduct that the U.S. Food and Drug Administration (FDA):\n\na. has licensed, and determined to meet the standards for\n\ninterchangeability pursuant to 42 U.S.C., Section\n\n262(k)(4), or\n\nb. has determined is therapeutically equivalent as set\n\nforth in the latest edition of or supplement to the\n\nUnited States Food and Drug Administration's (FDA)\n\nApproved Drug Products with Therapeutic Equivalence\n\nEvaluations.\n\nB. A pharmacist may substitute an interchangeable biological\n\nproduct for a prescribed biological product if:\n\n1. The substituted product has been determined by FDA to be\n\ninterchangeable, as defined in subsection A of this section, with\n\nthe prescribed biological product;\n\n2. The prescribing health care provider does not express a\n\npreference against substitution in writing, verbally or\n\nelectronically; and\n\n3. The pharmacy informs the patient of the substitution.\n\nC. The dispensing pharmacist or the pharmacist's designee shall\n\nmake an entry into an electronic records system of the specific\n\nproduct provided to the patient including the name of the product\n\nand the manufacturer. The communication shall be conveyed by making\n\nan entry through:\n\n1. An interoperable electronic medical records system;\n\n2. An electronic prescribing technology;\n\n3. A pharmacy benefit management system; or\n\n4. A pharmacy record.\n\nD. Entry into an electronic records system as described in\n\nsubsection C of this section is presumed to provide notice to the\n\nprescriber. If no electronic records system is in use by the\n\npharmacy, the pharmacist shall communicate the biological product\n\ndispensed to the prescriber using facsimile, telephone, electronic\n\ntransmission or other prevailing means, except that communication\n\nshall not be required where:\n\n1. There is no FDA-approved interchangeable biological product\n\nfor the product prescribed; or\n\n2. A refill prescription is not changed from the product\n\ndispensed on the prior filling of the prescription.\n\nE. The dispensing pharmacist or a prescriber shall not be:\n\n1. Required to show proof that the prescriber has access to the\n\nrecord in any type of payment audit conducted by a payer or pharmacy\n\nbenefit manager; or\n\n2. Subject to disciplinary action or civil penalties for\n\nfailure to ensure that the record is accessible or for failure to\n\naccess the record.\n\nF. The State Board of Pharmacy shall maintain a link on its\n\nInternet website to the current list of all biological products\n\ndetermined by the FDA to be interchangeable with a specific\n\nbiological product.\n\nG. Nothing in this section shall preclude existing approved\n\nbrand and generic substitutions.","path":["OK Code","Title 59"],"source_url":"https://www.oklegislature.gov/OK_Statutes/CompleteTitles/os59.pdf","current_through":"2026-08-14","vintage":"open-us-law v2026.08, retrieved 2026-09-14","retrieved_at":"2026-09-14T18:32:36Z","sha256":"8b2d1c7ded679292258df3fecb3f4678134d3ef8008cbfc2c315c7788d50f198","source_id":"us-ok","stale":false,"prev":"us-ok/okla.-stat.-tit.-59-59-355.3","next":"us-ok/okla.-stat.-tit.-59-59-356"},"notice":"GroundRules: Original legal text. Not legal advice."}